Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Dengue Fever
Researchers from University of Malaya, Medical Department report details of new studies and findings in the area of dengue fever
November 26th, 2008
"A method to map the specific site on dengue virus envelope protein (E) that interacts with cells and a neutralizing antibody is developed using serially truncated dengue virus type 2 (DENV-2) E displayed on M13 phages as recombinant E-g3p fusion proteins. Recombinant phages displaying the truncated E consisting of amino acids 297-423 (EB2) and amino acids 379-423 (EB4) were neutralized by DENV-2 patient sera and the DENV-2 E-specific 3H5-1 monoclonal antibodies suggesting that the phages retained the DENV-2 E antigenic properties," scientists in Kuala Lumpur, Malaysia report. "The EB4 followed by EB2 recombinant phages bound the most to human monocytes (THP-1), African...
Source: Immunotherapy Weekly (2008-11-26)
|
